3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Neoplasms
10
Carcinoma, Renal Cell
8
Carcinoma, Hepatocellular
8
Melanoma
7
Carcinoma, Non-Small-Cell Lung
7
Endometrial Neoplasms
6
Thyroid Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
4
Thyroid Cancer, Papillary
3
Stomach Neoplasms
3
Neuroendocrine Tumors
3
Colorectal Neoplasms
3
Adenocarcinoma, Follicular
3
Ovarian Neoplasms
2
Osteosarcoma
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Glioma
2
Carcinoma, Transitional Cell
2
Carcinoma
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid cancer, medullary
1
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Thyroid Carcinoma, Anaplastic
1
Interventions
Pemetrexed
15
Cisplatin
13
pembrolizumab
6
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
cediranib
3
Radiotherapy
3
Gemcitabine
3
Carboplatin
3
amatuximab
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Everolimus
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tremelimumab
1
sodium thiosulfate
1
sargramostim
1
nintedanib
1
napabucasin
1
methoxyamine
1
liposomal doxorubicin
1
incomplete Freund's adjuvant
1
fresolimumab
1
durvalumab
1
defactinib
1
cixutumumab
1
bintrafusp alfa protein, human
1
bemcentinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma, Malignant
×
lenvatinib
×
Clear all
No trials found.